News

Indicated for growth hormone deficiency (GHD) patients aged 3 years and older, somatrogon-ghla is now FDA-approved to treat GHD following positive phase 3 data demonstrating non-inferiority, measured by annual height velocity at 12 months, compared to somatropin.

Finding may have implications as more people take care of aging relatives around the world.

Johnson & Johnson has announced positive safety and efficacy results in a phase 2 trial evaluating nipocalimab against early-onset severe hemolytic disease of the fetus and newborn.

Nicole Peña Sahdala, MD, internist, gastroenterologist specialist in bariatric endoscopy, ABIM certified, discusses the rise in bariatric surgery among youth, and why other forms of care, such as lifestyle changes and education, are essential before any surgery is performed.

About 1 in 4 children are exposed to intimate partner violence (IPV) in their lifetime, according to the American Academy of Pediatrics. The AAP has released tips and recommendations for pediatricians to help support these patients and their families.

The days of “bad ‘bots” are behind us so put smart virtual assistants to work in your practice to reduce call volume, deliver self-service options to patients and improve operational efficiency.

Donnas Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the June issue of Contemporary Pediatrics®.

After Owlet’s baby-monitoring Smart Sock was pulled from the market in 2021, the FDA has cleared the company’s BabySat pulse oximetry sock for infants, capable of monitoring and alerting parents of pulse rate and oxygen saturation levels.

Today's hospitals and medical practices face the challenge of remaining relevant in an extremely dynamic, competitive, and evolving market.

After receiving accelerated approval, delandistrogene moxeparvovec-rokl is the first gene therapy to treat Duchenne muscular dystrophy (DMD) in ambulatory pediatric patients aged 4 to 5 years.

In a large observational study, significant information was obtained about protection against acute infection and disease severity in this age group.

In this Contemporary Pediatrics® interview, Dave Little, MD, MS, Physician Informaticist at Epic, discusses the importance of lipid screening in the pediatric population, specifically for children aged 9 to 11 years and those aged 2 to 8 years with increased risk of diabetes, obesity, or high blood pressure. Little says awareness of lipid screenings at the provider and parent levels can lead to more screenings overall, which can lead to healthier lifestyles for children.

Children 10 years and older with type 2 diabetes (T2D) can now be treated with empagliflozin and empagliflozin plus metformin hydrochloride to improve blood sugar control, per a recent approval by the FDA.

Links between teenager anxiety and gastrointestinal (GI) issues are the subject of this Contemporary Pediatrics® interview with Julia Anderson, MD, MSCI; and Sara Francis, PhD.

A family-centered procedural sedation protocol for children with autism spectrum disorder (ASD) or developmental delay (DD) allowed 93% of patients to be free of restraints during routine health care procedures.

Based on results from a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, find out how comfortable parents feel when it comes to abdominal pain in their child, and how likely they are to handle the issue themselves, or to reach out to a health care provider for help.

While monitoring sleep durations (TST) across 3 different time in bed (TIB) conditions, investigators determined advancing bedtime increases sleep duration for those aged 10 to 21 years.

These new guidelines were developed to benefit younger patients with inflammatory skin diseases, and may be helpful given the inexpensive nature and general availability of the drug.

One lasting legacy of COVID-19 is acceleration of patients’ acceptance of remote care management technology.

In a recent study, bonding scores did not change among infants receiving music therapy compared to those receiving standard care.

Prevention and treatment strategies for tick-borne diseases and respiratory infections

With a newly FDA-approved indication, odevixibat can now be used to treat cholestatic pruritus in patients 12 months and up with Alagille syndrome (ALGS).

After 12 weeks of treatment, 55.8% of participants receiving IDP-126 experienced at least a 70% reduction from baseline in inflammatory and noninflammatory lesions

Infant formula companies add new ingredients to match or best mimic human milk and breastfeeding advantage for the child, but comparing new-ingredient formulas with existing formulas and human milk to determine efficaciousness can present clinical and ethical challenges.

The infant did not show signs of illness; her mother experienced a routine pregnancy and prenatal lab test results were normal. What is the diagnosis?

The American Medical Association is asking doctors to scale back the use of the body mass index (BMI) when assessing obesity and health in patients, noting it should be used jointly with other measurements, and not solely. 

In a recent commentary, the NIH and FDA are urging leaders to increase research on drug-detection tools such as fentanyl test strips, along with removing barriers to access.

Kirk Thame, MD, associate professor, pediatric gastroenterology, hepatology, and nutrition, Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, explains how linaclotide differs from other treatment options for pediatric functional constipation, and why children will benefit from its recent FDA approval.